Study #2020-1173
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
MD Anderson Study Status
Not Accepting
Treatment Agent
LY3484356, Abemaciclib, Aromatase Inhibitor (AI), Everolimus, Alpelisib, Trastuzumab, Pertuzumab
Description
The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
Study phase:
Phase I
Physician name:
Rachel Layman
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-866-407-7176
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.